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INTRODUCTION
Bordella bronchiseptica is an obligate aerobic, nonfermenta-
tive gram negative coccobacillus that tests positive for motil-
ity, catalase, oxidase, urease, and nitrate reduction (1-5, 10).
Although it is commonly found as either a commensal or a
cause of respiratory tract disease in many wild and domestic
animals, it has very rarely been implicated as a cause of infec-
tion in humans (1). A few cases of infections in animal care-
takers, laboratory workers and immunocompromised patients
have been reported (2-5, 14-18).
Continuous ambulatory peritoneal dialysis (CAPD) is an
important and lifesaving form of renal replacement therapy
in patients with end-stage renal disease (ESRD). However,
peritonitis is a major complication that causes significant
morbidity and mortality in ESRD patients with CAPD (6-
9). Here, we report a case of relapsing CAPD peritonitis
caused by B. bronchiseptica; the first case of a human infec-
tion in Korea. 
CASE REPORT
A 56-yr-old male, treated with CAPD for ESRD secondary
to gout for 13 yr, was admitted with complaints of a febrile
sense and abdominal pain. The indwelling Tenckhoff catheter
was cared for appropriately and there was no physical contact
with animals. On admission, the temperature was 37.6℃
and the abdominal examination showed diffuse abdominal
tenderness. The initial laboratory data included a hemoglobin
of 10.6 g/dL, leucocytes 8,960/μ L with 73.9% of neutrophils,
blood urea nitrogen/creatinine (BUN/Cr) 42/10.2 mg/dL,
aspartate aminotransferase/alanine transaminase (AST/ALT)
37/44 IU/L, total protein/albumin 5.7/3.3 g/dL, and C-reac-
tive protein (CRP) 6.52 mg/dL. The peritoneal dialysate was
turbid, and contained 5,100/μ L leucocytes with 99% of neu-
trophils and gram-negative coccobacilli (Fig. 1). Culture of
the peritoneal dialysate on sheep blood agar grew 0.5-1.0 mm
sized flat, grey-white, non-hemolytic colonies after 24 hr of
incubation at 35℃ and 5-10% CO2 (Fig. 2). The organism
was a gram negative coccobacillus (Fig. 3), and also grew read-
ily on MacConkey and salmonella-shigella agar. The organ-
ism tested positive for motility, catalase, oxidase, urease, and
nitrate reduction, but did not ferment any carbohydrates. The
isolated organism was finally identified as B. broanchiseptica
(bionumber of GNI card: 000000130400000) by the Vitek
II compact system (bioMeriux, Marcy-I’Etoile, France). The
results of the susceptibility testing with an AST-N055 kit,
from the Vitek II compact system (bioMeriux, Marcy-I’Etoile,
France), showed resistance to minocyclin (>16 μ g/mL) and
trimethoprime/sulfamethoxazole (>80 μ g/mL), but suscep-
tibility to other antibiotics such as ticarcillin, piperacillin,
cefotaxime, ceftazidime, cefepime, aztreonam, imipenem,
amikacin, gentamicin, tobramycin, and ciprofloxacin. Initial-
ly, according to our standard protocol, the patient was provi-
sionally treated with intraperitoneal antibiotics, consisting
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Relapsing Peritonitis Caused by Bordetella bronchiseptica in 
Continuous Ambulatory Peritoneal Dialysis Patient: A Case Report
Bordetella (B) bronchiseptica is a common veterinary pathogen, but has rarely been
implicated in human infections. Most patients with B. bronchiseptica infections are
compromised clinically such as in patients with a malignancy, AIDS, malnutrition,
or chronic renal failure. We experienced a case of relapsing peritonitis caused by
B. bronchiseptica associated with continuous ambulatory peritoneal dialysis (CAPD).
A 56-yr-old male, treated with CAPD due to end stage renal disease (ESRD), was
admitted with complaints of abdominal pain and a turbid peritoneal dialysate. The
culture of peritoneal dialysate identified B. bronchiseptica. The patient was treated
with a combination of intraperitoneal antibiotics. There were two further episodes
of relapsing peritonitis, although the organism was sensitive to the used antibiotics.
Finally, the indwelling CAPD catheter was removed and the patient was started on
hemodialysis. This is the first report of a B. bronchiseptica human infection in the
Korean literature. 
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Accepted : 10 December 2008of ceftazidime and ceftezole (each 1 g per 2-liter bag). The
abdominal pain and turbid dialysate resolved within four days.
The blood cultures obtained simultaneously prior to starting
the antibiotics were negative. The nasal swab and culture were
also negative. There was no evidence of an infectious source
or animal contact. We continued the antibiotic therapy for
two weeks, and the culture of peritoneal dialysate showed no
growth at that time. After then, there were two episodes of
relapsing peritonitis caused by the same organism. At first
relapse, we considered the removal of the Tenckhoff catheter,
the patient refused because there were no hemodialysis facil-
ities in his residential area. The peritonitis was subsided after
three days of treatment with intraperitoneal ceftazidime and
amikacin. We kept the antibiotic therapy for three weeks, and
the culture of peritoneal dialysate showed no growth. The fol-
lowing month, a peritonitis due to the same organism recurred
one more time. With the consent of the patient, we removed
the Tenckhoff catheter. The patient was treated with intra-
venous ceftazidime and amikacin for two weeks, and trans-
ferred to hemodialysis. He is doing well.
DISCUSSION
B. bronchiseptica is known to cause respiratory tract infec-
tions in mammals. It has rarely been isolated from humans
despite the considerable exposure of humans to animal sources
of the microorganism (1, 3, 4, 11). It may occasionally be
encountered as a commensal organism or as a colonizer of
the human respiratory tract. It has rarely been identified as
a pathogen in humans with underlying disease or immuno-
compromise (1-5, 12, 14-18). A history of exposure to ani-
mals may be significant but is not essential for B. bronchisep-
tica human infections (2, 19). In this case, the source of the
infection was not found because there was no history of expo-
sure to animals; the nasal swab and culture provided no addi-
tional information. However, the fact that the patient was
an immunocompromised ESRD patient with CAPD, and
had lived in an agricultural setting might have been risk
factors for B. bronchiseptica infection.
B. bronchiseptica is an obligate aerobic, nonfermentative,
gram negative coccobacillus that grows readily on simple
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Fig. 1. Gram-stained smear of peritoneal dialysate showing scat-
tered gram-negative coccobacilli (arrows) among neutrophils.
Fig. 2. Sheep blood agar plate showing 1-2 mm sized, raised,
grayish-white colonies after 48 hr incubation at 37°C, 5%-CO2.
Fig. 3. Gram-stained smear of colony on BAP after 48 hr incuba-
tion at 37°C showing gram negative coccobacili.nutritive media at 35℃. It is positive for catalase, oxidase,
citrate utilization, motility, urease, nitrate reduction, tetra-
zolium reduction, and growth on salmonella-shigella agar,
and it is negative for indole, acid production in oxidation-
fermentation glucose and maltose media, tyrosine hydroly-
sis, and growth on tellurite agar (1-3, 5). B. bronchiseptica is
distinguished from other fastidious Bordetella species, B. per-
tusis and B. parapertusis, by its easy growth on simple nutri-
ent agar and its rapid urease positivity, as well as its ability
to reduce nitrate to nitrite, and its motility (1). Motile, glu-
cose-negative, nonfermentative bacilli are difficult to identi-
fy by the commonly used procedures in clinical laboratories
(10). B. bronchiseptica can be confused with the Alcaligenes
species, CDS group IVC-2 and group IVe, which have been
reported to have different carbon substrate utilization pat-
terns (3). The organism isolated from the peritoneal dialysate
of our patient grew readily on BAP, MacConkey and SS agar
at 35℃. It was identified as B. bronchiseptica by the Vitek II
compact system (bioMeriux, Marcy-I’ Etoile, France).
From recent in vitro antimicrobial susceptibility studies
of B. bronchiseptica, the most effective agents for treatment
appear to be aminoglycosides, antipseudomonal penicillins,
broad-spectrum cephalosporins, tetracyclines and chloram-
phenicol (1, 20). However, several reports have emphasized
a poor correlation between the in vitro antibiotic suscepti-
bility of B. bronchiseptica and the clinical response (4). In our
patient, the results of the susceptibility tests showed resis-
tance only to minocyclin and trimethoprime/sulfamethoxa-
zole, and susceptibility to all other antibiotics. The cause of
the frequent relapses in our patient is unclear; the patient
was treated with intraperitoneal antibiotics, initially consist-
ing of ceftazidime and ceftezole, and with ceftazidime and
amikacin after relapse. The testing showed that the B. bron-
chiseptica cultured from peritoneal dialysate was sensitive to
these antibiotics. About the poor outcome of this patient, a
question arises: What is the most appropriate treatment strat-
egy? It is also possible B. bronchiseptica colonized the Tenck-
hoff catheter because two weeks of initial antibiotic therapy
might have been inadequate to eradicate the organism com-
pletely. And, it may be necessary to consider catheter-relat-
ed infection caused by colonization of this organism.
Peritonitis is a major and potentially serious complication
of CAPD (6-9, 13). Recurrent episodes of peritonitis are asso-
ciated with fibrosis of the peritoneal membrane, and eventu-
ally loss of the dialysis efficiency and failure of the technique
(8). In 1981, Lawrence et al. first reported B. bronchiseptica
peritonitis associated with CAPD (3). This is the first Kore-
an report of a B. bronchiseptica human infection, associated
with CAPD. Our experience suggests that B. bronchiseptica
infection should be considered in the differential diagnosis
of patients in contact with domestic animals and/or immuno-
compromised patients. In addition, it may be necessary to
consider early removal of Tenckhoff catheter in the case of
CAPD peritonitis caused by this organism. 
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